期刊
CURRENT ALLERGY AND ASTHMA REPORTS
卷 17, 期 3, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-017-0687-0
关键词
Immunotherapy and tolerance induction; Regulatory aspects; Allergic rhinitis; Trial design
资金
- Merck & Co., Inc., Kenilworth, NJ, USA
Progress has been made in the harmonization of efficacy and safety outcome measures for allergen immunotherapy (AIT) trials, but unresolved issues still remain. Furthermore, there are discrepancies in recommendations from professional medical societies and regulatory agencies regarding requirements for AIT trials. In this article, we reviewed published recommendations and current data from recent clinical trials, as well as the criteria applied by regulatory authorities for approval of AIT products, to provide updated considerations for conducting phase 3 AIT trials. Topics discussed include analysis of outcomes and trial designs for pediatric and asthma indications, as well as trial designs for perennial allergic rhinoconjunctivitis. In addition, the need for harmonization of safety reporting is emphasized. Considerations presented in this article may further effort to find common ground among professional medical societies and government agencies in developing future recommendations for AIT trial design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据